OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females

Summary

This study will evaluate the safety and efficacy of onabotulinumtoxinA (BOTOX®) compared with placebo as treatment for major depressive disorder (MDD) in adult females.

Timeline

Start

2014-04-22

Primary completion

2016-08-25

Completion

2016-12-22

Outcome

Missed primary endpoint

paper OnabotA 30 U approached significance compared to placebo on MADRS (mixed-effect model repeated measures least-squares mean difference: -3.7; P = 0.053) PMID 31609787 ↗

Publications

• Brin MF, Durgam S, Lum A, James L, Liu J, Thase ME, Szegedi A. OnabotulinumtoxinA for the treatment of major depressive disorder: a phase 2 randomized, double-blind, placebo-controlled trial in adult females. Int Clin Psychopharmacol. 2020 Jan;35(1):19-28. doi: 10.1097/YIC.0000000000000290.

Drugs

Indications